Avestar Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Avestar Capital’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-311	Closed	-$8K	–	1044
2018 Q3	$8K	Hold	311	–	–	﹤0.01%	502
2018 Q2	$6K	Hold	311	–	–	﹤0.01%	555
2018 Q1	$5K	Hold	311	–	–	﹤0.01%	551
2017 Q4	$4K	Buy	+311	New	+$4.2K	﹤0.01%	590

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Avestar Capital's MNTA Position: Q4 2018 in Review

Avestar Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2018, closing a stake of 311 shares — an estimated $8K sold.

Avestar Capital first reported a position in MNTA in Q4 2017 and held it in 4 quarters. The position peaked at $8K in Q3 2018. 158 funds tracked by Wall St. Rank hold MNTA as of Q4 2018.

Avestar Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Avestar Capital sold 311 Momenta Pharmaceuticals, Inc. shares in Q4 2018, an estimated $8K.
Avestar Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Avestar Capital's Momenta Pharmaceuticals, Inc. position peaked at $8K in Q3 2018.
158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2018.

Based on Avestar Capital's 13F filing for Q4 2018, filed 25 Jan 2019.